ProfileGDS5678 / 1432961_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 56% 56% 54% 55% 58% 57% 59% 55% 56% 56% 55% 56% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5059757
GSM967853U87-EV human glioblastoma xenograft - Control 23.4000456
GSM967854U87-EV human glioblastoma xenograft - Control 33.4008656
GSM967855U87-EV human glioblastoma xenograft - Control 43.2879454
GSM967856U87-EV human glioblastoma xenograft - Control 53.3143155
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5739858
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5575857
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5347859
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3517855
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4167456
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4053456
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3356655
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4390856
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4062956